On October 11, 2021 Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, reported that it will present early clinical data for repotrectinib from the ongoing Phase 1/2 CARE study in pediatric and young adult patients with advanced solid tumors harboring ALK, ROS1 or NTRK alterations at the virtual 53rd Congress of the International Society of Paediatric Oncology (SIOP) being held October 21-24 (Press release, Turning Point Therapeutics, OCT 11, 2021, View Source [SID1234591109]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details for the Presentation
Presentation Title: A Phase 1/2, open-label study of repotrectinib in pediatric and young adult patients with advanced or metastatic malignancies harboring ALK, ROS1, or NTRK1-3 alterations
Session Name: 910 – FPS 04-Live Q&A-New Drugs/Experimental Therapeutics
Session Type: Free Paper Session (FPS)
Date / Session Time: Saturday, October 23, 2021, 8:40 – 9:40 a.m. ET
Lecture Time: 9:12 – 9:22 a.m. ET
Presenter: Steven G. Dubois, M.D., Associate Professor of Pediatrics, Harvard Medical School, Director, Experimental Therapeutics for Pediatric Oncology, Dana-Farber Cancer Institute
The presentation from SIOP 2021 will be available on the company’s website shortly after the event at www.tptherapeutics.com.